SCHEMBL23510450

SCHEMBL23510450

O=C1NC(Nc2ccccc2)=N/C1=C\c1ccc2ncsc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 17/20 1.00
▸ DYRK3 O43781 15/20 1.00
▸ DYRK2 Q92630 15/20 1.00
▸ DYRK1B Q9Y463 15/20 1.00
▸ CLK1 P49759 14/20 1.00
▸ CLK4 Q9HAZ1 14/20 1.00
▸ CLK2 P49760 13/20 1.00
▸ CLK3 P49761 10/20 1.00
▸ DYRK4 Q9NR20 9/20 1.00
▸ GSK3B P49841 8/20 1.00
▸ CSNK1E P49674 1/20 0.69
▸ CSNK2A2 P19784 5/20 0.62
▸ CSNK2B P67870 5/20 0.62
▸ CSNK2A1 P68400 5/20 0.62
▸ CSNK2A3 Q8NEV1 5/20 0.62
▸ PIM1 P11309 4/20 0.62
▸ CNR1 P21554 2/20 0.59
▸ GSK3A P49840 2/20 0.58
▸ CCNT1 O60563 1/20 0.58
▸ CDK9 P50750 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29899879 1.00 DYRK1A (1.00) DYRK1ADYRK3DYRK2DYRK1BCLK1
SCHEMBL29015886 1.00 DYRK1A (1.00) DYRK1ADYRK3DYRK2DYRK1BCLK1
SCHEMBL29899908 0.91 DYRK1A (0.84) DYRK1ADYRK3DYRK2DYRK1BCLK1
SCHEMBL24904279 0.91 DYRK1A (0.84) DYRK1ADYRK3DYRK2DYRK1BCLK1
SCHEMBL28953211 0.91 DYRK1A (0.84) DYRK1ADYRK3DYRK2DYRK1BCLK1
SCHEMBL23510515 0.91 DYRK2 (0.84) DYRK1ADYRK3DYRK2DYRK1BCLK1
SCHEMBL29899824 0.91 DYRK2 (0.84) DYRK1ADYRK3DYRK2DYRK1BCLK1
SCHEMBL23970384 0.90 DYRK1A (1.00) DYRK1ADYRK3DYRK2DYRK1BCLK1
SCHEMBL25590093 0.90 DYRK3 (0.81) DYRK1ADYRK3DYRK2DYRK1BCLK1
SCHEMBL24904295 0.89 DYRK2 (0.81) DYRK1ADYRK3DYRK2DYRK1BCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114929690-B Novel heterocyclic derivatives having cardiomyocyte proliferative activity for the treatment of heart disease 同济大学 2023-05-05 — — CN disclosed
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TONGJI UNIVERSITY (CN) 2023-01-26 — — US disclosed
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TONGJI UNIVERSITY (CN) 2023-01-26 — — US disclosed
WO-2021115489-A1 NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES TONGJI UNIVERSITY (CN) 2021-06-17 — — WO disclosed
WO-2021114314-A1 NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES TONGJI UNIVERSITY (CN) 2021-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TNNI3, TNNT2, MKI67 DYRK1A 3319/4885DYRK3 2851/4885DYRK2 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback